Procainamide Dosing
For adults with ventricular arrhythmias, administer IV procainamide as a loading dose of 20-50 mg/min until arrhythmia suppression, hypotension, QRS widening by 50%, or a maximum cumulative dose of 17 mg/kg (or 1 gram), followed by maintenance infusion of 1-4 mg/min (typically 2-6 mg/min). 1
Adult IV Dosing
Loading Dose - Two Options:
Option 1: Intermittent Bolus
- Administer 100 mg IV every 5 minutes at a rate not exceeding 50 mg/min
- Continue until arrhythmia suppression or 500 mg total administered
- Wait 10+ minutes before resuming if 500 mg reached
- Maximum total loading dose: 1 gram 2
Option 2: Continuous Loading Infusion (preferred)
- Dilute 1 gram to 50 mL (20 mg/mL concentration)
- Infuse at 1 mL/min for 25-30 minutes (delivers 500-600 mg)
- Effects typically seen after 100-200 mg
- Maximum total loading dose: 1 gram 3
Stop loading if:
- Arrhythmia suppressed
- Hypotension develops
- QRS prolonged by 50%
- Maximum dose reached 1
Maintenance Infusion:
Standard concentration: 2 mg/mL (1 gram in 500 mL D5W)
- Infuse at 1-3 mL/min (delivers 2-6 mg/min) 2
Fluid-restricted concentration: 4 mg/mL (1 gram in 250 mL D5W)
- Infuse at 0.5-1.5 mL/min (delivers 2-6 mg/min) 2
Typical maintenance rate: 50 mcg/min/kg body weight produces plasma level ~6.5 mcg/mL in patients with normal renal function 2
Adult Oral Dosing
Sustained-release formulation: 500-1250 mg every 6 hours 4
Immediate-release formulation: Dosed every 3-4 hours (less commonly used due to frequent dosing) 5, 6
Transition from IV to oral after 3-4 hours (one elimination half-life) following last IV dose 2
Pediatric Dosing
IV loading: 15 mg/kg IV/IO over 30-60 minutes 7
Maintenance: Not specifically detailed in pediatric guidelines, but adult dosing principles apply with weight-based adjustments 7
Renal Dose Adjustments
Critical consideration: Procainamide and its active metabolite NAPA are primarily renally eliminated 3
Age-related reductions (independent of creatinine clearance):
- Age 50: ~25% reduction in renal excretion
- Age 75: ~50% reduction in renal excretion 2
Renal impairment adjustments:
- Reduce maintenance infusion rate proportionally to degree of renal dysfunction
- Monitor plasma levels closely
- NAPA accumulation increases torsades de pointes risk 3
CRRT patients: Consider 50% reduction in maintenance dose (from 4 mg/min to 2 mg/min) based on pharmacokinetic modeling 8
Critical Safety Monitoring
Terminate infusion immediately if:
- Persistent conduction disturbances develop
- Hypotension occurs
- QRS widens by ≥50% 2
Avoid procainamide in:
- QT prolongation (risk of torsades de pointes)
- Heart failure with reduced ejection fraction
- Renal insufficiency without dose adjustment 1
Monitor continuously:
- ECG (QRS duration, QT interval)
- Blood pressure
- Clinical response 3
Clinical Context
Procainamide is indicated for hemodynamically stable monomorphic VT, pre-excited atrial fibrillation, and wide-complex tachycardias of uncertain mechanism 1. Recent evidence suggests procainamide may be superior to amiodarone for acute VT termination (67% vs 38% conversion rate) with fewer major cardiac adverse events (9% vs 41%) 9. However, it is typically not first-line therapy—lidocaine is generally preferred initially for ventricular arrhythmias in acute MI settings 3.